![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TEP1 |
Gene summary for TEP1 |
![]() |
Gene information | Species | Human | Gene symbol | TEP1 | Gene ID | 7011 |
Gene name | telomerase associated protein 1 | |
Gene Alias | TLP1 | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000722 | UniProtAcc | G3V5X7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7011 | TEP1 | HCC1_Meng | Human | Liver | HCC | 5.51e-12 | 9.91e-03 | 0.0246 |
7011 | TEP1 | HCC2_Meng | Human | Liver | HCC | 3.49e-14 | 1.19e-01 | 0.0107 |
7011 | TEP1 | HCC1 | Human | Liver | HCC | 6.07e-13 | 1.25e+00 | 0.5336 |
7011 | TEP1 | HCC2 | Human | Liver | HCC | 2.99e-28 | 2.33e+00 | 0.5341 |
7011 | TEP1 | HCC5 | Human | Liver | HCC | 1.18e-16 | 9.99e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000072311 | Liver | HCC | telomere maintenance | 85/7958 | 131/18723 | 1.86e-07 | 3.40e-06 | 85 |
GO:000627811 | Liver | HCC | RNA-dependent DNA biosynthetic process | 50/7958 | 75/18723 | 2.02e-05 | 2.17e-04 | 50 |
GO:00718975 | Liver | HCC | DNA biosynthetic process | 99/7958 | 180/18723 | 4.66e-04 | 3.08e-03 | 99 |
GO:00322001 | Liver | HCC | telomere organization | 86/7958 | 159/18723 | 2.06e-03 | 1.04e-02 | 86 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TEP1 | SNV | Missense_Mutation | c.1699N>G | p.Leu567Val | p.L567V | Q99973 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TEP1 | SNV | Missense_Mutation | c.4531G>C | p.Glu1511Gln | p.E1511Q | Q99973 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-FU-A3HY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TEP1 | SNV | Missense_Mutation | rs767674334 | c.6406N>C | p.Glu2136Gln | p.E2136Q | Q99973 | protein_coding | tolerated(0.67) | benign(0) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TEP1 | SNV | Missense_Mutation | c.6934G>T | p.Ala2312Ser | p.A2312S | Q99973 | protein_coding | deleterious(0.02) | possibly_damaging(0.721) | TCGA-Q1-A73Q-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
TEP1 | SNV | Missense_Mutation | c.1699N>G | p.Leu567Val | p.L567V | Q99973 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
TEP1 | SNV | Missense_Mutation | novel | c.3905G>A | p.Gly1302Asp | p.G1302D | Q99973 | protein_coding | deleterious(0.04) | possibly_damaging(0.713) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEP1 | SNV | Missense_Mutation | c.7145G>A | p.Gly2382Asp | p.G2382D | Q99973 | protein_coding | deleterious_low_confidence(0.01) | benign(0.425) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TEP1 | SNV | Missense_Mutation | c.2546C>T | p.Ala849Val | p.A849V | Q99973 | protein_coding | deleterious(0.03) | benign(0.253) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TEP1 | SNV | Missense_Mutation | novel | c.2195N>A | p.Ala732Glu | p.A732E | Q99973 | protein_coding | tolerated(0.25) | benign(0.02) | TCGA-AA-3867-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
TEP1 | SNV | Missense_Mutation | rs548257852 | c.2740N>T | p.Arg914Trp | p.R914W | Q99973 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7011 | TEP1 | NA | V934/V935 |
Page: 1 |